Pathogenic basis of B cell targeted therapy in systemic lupus erythematosus (SLE);Bases patogénicas de la terapia dirigida a las células B en el lupus eritematoso sistémico (LES)

Reumatologia Clinica

Volumn 6, Issue SUPPL. 2, 2010, Pages 21-24

  Pablos Álvarez, Jose Luis ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

B lymphocytes; Rituximab; Systemic lupus erythematosus; Therapy

Indexed keywords

AMG 623; APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; BRIOBACEPT; CD19 ANTIBODY; CD20 ANTIBODY; DNA ANTIBODY; EPRATUZUMAB; MDX 1342; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BASAL CELL; CLINICAL TRIAL; CYTOLYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; LYMPHOCYTE DEPLETION; PATHOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); TARGET CELL;

EID: 84871509619     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.04.003     Document Type: Article

References (28)

1. Weisbart R.H., Colburn K. Effect of corticosteroids on serum antinuclear antibodies in man. Immunopharmacology 1984, 8:97-101.
2. McCune W.J., Fox D. Intravenous cyclophosphamide therapy of severe SLE. Rheum Dis Clin North Am 1989, 15:455-477.
3. Edwards J.C., Leandro M.J., Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 2005, 8:175-192.
4. Dörner T., Radbruch A., Burmester G.R. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009, 5:433-441.
5. Jacobi A.M., Goldenberg D.M., Hiepe F., Radbruch A., Burmester G.R., Dörner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67:450-457.
6. Cancro M.P., D'Cruz D.P., Khamashta M.A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119:1066-1073.
7. Cambridge G., Leandro M.J., Teodorescu M., Manson J., Rahman A., Isenberg D.A., et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006, 54:3612-3622.
8. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146-2154.
9. Leandro M.J., Cooper N., Cambridge G., Ehrenstein M.R., Edwards J.C. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007, 46:29-36.
10. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008, 67:917-925.
11. Vital EM, Dass S, Rawstron AC, Buch MH, Goëb V, Henshaw K, et al. Management of non-response to rituximab in rheumatoid arthritis: Predictors and outcome of retreatment. Arthritis Rheum. 2010 Jan 25. [Epub ahead of print].
12. Dass S., Rawstron A.C., Vital E.M., Henshaw K., McGonagle D., Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999.
13. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006, 5:564-576.
14. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.
15. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
16. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
17. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
18. Bingham 3rd C.O., Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
19. Huang H., Benoist C., Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010, 107:4658-4663.
20. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
21. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
22. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
23. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
24. Furie R., Looney R.J., Rovin B., Latinis K.M., Appel G., Sánchez-Guerrero J., et al. Efficacy and Safety of Rituximab in Subjects with Active Proliferative Lupus Nephritis (LN): Results From the Randomized, Double-Blind Phase III LUNAR Study. Arthritis Rheum 2009, 60(Suppl 10):1149.
25. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., et al. A phase ii, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178.
26. Looney R.J., Anolik J., Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010, 20:1-10.
27. Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005, 78:275-280.
28. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010 Feb 3. [Epub ahead of print].